Chengxin Deng
About
In The Last Decade
Chengxin Deng
21 papers receiving 292 citations
Peers
Comparison fields: 5 of 46
- Hematology 176
- Genetics 167
- Molecular Biology 76
- Immunology 61
- Surgery 45
Countries citing papers authored by Chengxin Deng
This map shows the geographic impact of Chengxin Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengxin Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengxin Deng more than expected).
Fields of papers citing papers by Chengxin Deng
This network shows the impact of papers produced by Chengxin Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengxin Deng. The network helps show where Chengxin Deng may publish in the future.
Co-authorship network of co-authors of Chengxin Deng
This figure shows the co-authorship network connecting the top 25 collaborators of Chengxin Deng. A scholar is included among the top collaborators of Chengxin Deng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengxin Deng. Chengxin Deng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 3 | |
| 5 | 1 | |
| 6 | 6 | |
| 7 | 3 | |
| 8 | Concurrence of Myelodysplastic syndromes and large granular lymphocyte leukemia: clinicopathological features, mutational profile and gene ontology analysis in a single center. | 6 |
| 9 | 6 | |
| 10 | 3 | |
| 11 | 0 | |
| 12 | 1 | |
| 13 | A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center. | 4 |
| 14 | Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs. | 16 |
| 15 | Premature exhaustion of mesenchymal stromal cells from myelodysplastic syndrome patients. | 10 |
| 16 | 7 | |
| 17 | 6 | |
| 18 | 2 | |
| 19 | 11 | |
| 20 | 26 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.